Zobrazeno 1 - 10
of 989
pro vyhledávání: '"epidermal growth factor receptor‐tyrosine kinase inhibitor"'
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background There are some changes in the new 9th edition Tumor-Node-Metastases (TNM) staging system for lung cancer, including subdividing M1c into M1c1 and M1c2 stage. The aim of this study was to assess the prognostic performance of the up
Externí odkaz:
https://doaj.org/article/82ff8c6d670744eaa70a2d8329d79185
Publikováno v:
Egyptian Journal of Chest Disease and Tuberculosis, Vol 73, Iss 3, Pp 290-301 (2024)
Objective One of the main obstacles to treating patients with non-small-cell lung cancers (NSCLC) is the emergence of drug resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Aim To investigate the progno
Externí odkaz:
https://doaj.org/article/c50ad990d0ef4ca280a0be0f5f96b196
Publikováno v:
Jichu yixue yu linchuang, Vol 44, Iss 5, Pp 658-664 (2024)
Objective To explore the correlation between circulating lymphocyte profiles and the outcomes of non-small cell lung cancer (NSCLC) patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. Methods A retrospec
Externí odkaz:
https://doaj.org/article/de9dcede191e425c99351fb7b6268578
Autor:
Yoshihiro Go, Chinatsu Yoshizaki, Yuki Yoshida, Shiho Nohmi, Rui Kusakado, Yuichiro Saito, Kensuke Izumizaki, Takafumi Ogawa, Takashi Suzuki, Fumihiro Yamaguchi
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 16, Iss , Pp 100329- (2024)
The use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is well-established for the treatment of advanced non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. In this study, we report the long-term ef
Externí odkaz:
https://doaj.org/article/1065f93686de47658f71f7a8381fa71c
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundOsimertinib, a third-generation tyrosine kinase inhibitor (TKI), has demonstrated significant efficacy in treating non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, EGFR-TKI-induced
Externí odkaz:
https://doaj.org/article/596cde0bed4f47279799f48de255daa5
Autor:
Jung-Yueh Chen, Sheng-Kai Liang, Tzu-Yi Chuang, Chia-Yu Chu, Chia-Hung Tu, Yu-Jo Yeh, Yu-Feng Wei, Kuan-Yu Chen
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 2, Pp 198-207 (2024)
Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are used as the standard first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). However, the impact of comorbidities and tre
Externí odkaz:
https://doaj.org/article/35cd2d64adf249559b93739c6530ae0d
Publikováno v:
Taiwan Journal of Ophthalmology, Vol 14, Iss 1, Pp 121-124 (2024)
This case discussed a significant ocular side effect, bilateral keratitis, which could be induced by afatinib, an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). We explored the disease progression of a 52-year-old
Externí odkaz:
https://doaj.org/article/40f7934395794b0695d91c832981f2d6
Autor:
Tian Gan, Jindong Chen, Hao Wang, Conghui Shang, Siqi Xi, Zixu Fan, Ben He, Min Zhang, Liang Zhao
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo evaluate the impact of sequential (first- to third-generation) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment on top-corrected QT interval (top-QTc) in non-small cell lung cancer (NSCLC) patients.MethodsWe
Externí odkaz:
https://doaj.org/article/55d2d51f4da2463bbf0ee2f3d05110ed
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Objective To elucidate the potential benefits of combining radiotherapy and epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) for individuals with Stage IV lung adenocarcinoma (LUAD) harboring either exon 19 deletio
Externí odkaz:
https://doaj.org/article/fe877c2c322344bda60d0f0b36daf2c9
Publikováno v:
BMC Complementary Medicine and Therapies, Vol 23, Iss 1, Pp 1-23 (2023)
Abstract Objective This study aimed to explore the efficacy and safety of combining epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with ZiLongJin Tablet (ZLJT) in delaying acquired resistance in advanced EGFR-mutant lung aden
Externí odkaz:
https://doaj.org/article/3823770dc37a47bf8865d464d9f65823